Regular
NAV (25-Jul-24)
Returns (Since Inception)
Fund Size
₹713 Cr
Expense Ratio
2.36%
ISIN
INF209KB1N91
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
11 Jul 2019
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+46.29%
+45.90% (Cat Avg.)
3 Years
+14.68%
+14.66% (Cat Avg.)
5 Years
+23.51%
+26.30% (Cat Avg.)
Since Inception
+23.57%
— (Cat Avg.)
Equity | ₹689.06 Cr | 96.59% |
Others | ₹24.36 Cr | 3.41% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹104.37 Cr | 14.63% |
Cipla Ltd | Equity | ₹62.21 Cr | 8.72% |
Torrent Pharmaceuticals Ltd | Equity | ₹54.35 Cr | 7.62% |
Apollo Hospitals Enterprise Ltd | Equity | ₹45.73 Cr | 6.41% |
Aurobindo Pharma Ltd | Equity | ₹41.21 Cr | 5.78% |
Fortis Healthcare Ltd | Equity | ₹34.58 Cr | 4.85% |
Zydus Lifesciences Ltd | Equity | ₹33.27 Cr | 4.66% |
Ajanta Pharma Ltd | Equity | ₹29.58 Cr | 4.15% |
Gland Pharma Ltd | Equity | ₹28.49 Cr | 3.99% |
Lupin Ltd | Equity | ₹26.62 Cr | 3.73% |
Clearing Corporation Of India Limited | Cash - Repurchase Agreement | ₹25.13 Cr | 3.52% |
Alkem Laboratories Ltd | Equity | ₹24.84 Cr | 3.48% |
Abbott India Ltd | Equity | ₹22.08 Cr | 3.10% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹21.57 Cr | 3.02% |
Alembic Pharmaceuticals Ltd | Equity | ₹21.06 Cr | 2.95% |
Dr Reddy's Laboratories Ltd | Equity | ₹20.36 Cr | 2.85% |
Strides Pharma Science Ltd | Equity | ₹19.26 Cr | 2.70% |
Jupiter Life Line Hospitals Ltd | Equity | ₹17.06 Cr | 2.39% |
Vijaya Diagnostic Centre Ltd | Equity | ₹16.55 Cr | 2.32% |
Sanofi India Ltd | Equity | ₹14.92 Cr | 2.09% |
Star Health and Allied Insurance Co Ltd | Equity | ₹13.66 Cr | 1.91% |
Mankind Pharma Ltd | Equity | ₹9.55 Cr | 1.34% |
Sanofi Consumer He | Equity | ₹8.6 Cr | 1.21% |
Medi Assist Healthcare Services Ltd | Equity | ₹7.88 Cr | 1.11% |
Vinati Organics Ltd | Equity | ₹7.39 Cr | 1.04% |
Medplus Health Services Ltd | Equity | ₹3.86 Cr | 0.54% |
Net Receivables / (Payables) | Cash | ₹-0.77 Cr | 0.11% |
Large Cap Stocks
41.57%
Mid Cap Stocks
35.65%
Small Cap Stocks
18.16%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹659.41 Cr | 92.43% |
Financial Services | ₹13.66 Cr | 1.91% |
Basic Materials | ₹7.39 Cr | 1.04% |
Standard Deviation
This fund
14.85%
Cat. avg.
14.65%
Lower the better
Sharpe Ratio
This fund
0.53
Cat. avg.
0.55
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
0.92
Higher the better
Since July 2019
Since November 2022
ISIN | INF209KB1N91 | Expense Ratio | 2.36% | Exit Load | 1.00% | Fund Size | ₹713 Cr | Age | 11 Jul 2019 | Lumpsum Minimum | ₹1,000 | Fund Status | Open Ended Investment Company | Benchmark | BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Flat 15% tax on realised gains (STCG - short term capital gains)
10% tax on realised gains above Rs. 1 lakh per financial year (LTCG - long term capital gains)
Note: Mutual funds are subject to capital gains taxation with surcharge and cess, based on prevailing income tax rules and investor income. Taxation applies to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹15.00 Cr | 46.7% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹713.42 Cr | 48.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹713.42 Cr | 46.3% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹29.73 Cr | 45.2% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹173.47 Cr | 45.0% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹173.47 Cr | 42.3% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2312.48 Cr | 45.8% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹2312.48 Cr | 43.7% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹638.88 Cr | 47.4% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹17.23 Cr | 44.1% |
Total AUM
₹3,61,512 Cr
Address
One World Centre, Tower 1, 17th Floor, Mumbai, 400 013
Your principal amount will be at Very High Risk